Korro Bio, Inc. ( (KRRO) ) has released its Q2 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Korro Bio, Inc., based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company specializing in genetic medicines through RNA editing for rare and prevalent diseases.
In its second quarter 2025 earnings report, Korro Bio highlighted significant progress in its clinical trials and strategic initiatives, including the ongoing Phase 1/2a REWRITE clinical trial for KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD).
Key financial metrics from the report show Korro ending the quarter with $119.6 million in cash and equivalents, a decrease from the previous quarter, while collaboration revenue increased to $1.5 million due to its partnership with Novo Nordisk. The company also reported a net loss of $25.8 million, reflecting increased R&D and administrative expenses.
Strategically, Korro Bio is advancing its pipeline with the European Medicines Agency granting orphan drug designation to KRRO-110 for AATD. The company is also progressing its collaboration with Novo Nordisk and expects to announce a new development candidate for a rare metabolic disorder by the end of 2025.
Looking ahead, Korro Bio remains focused on its 3-2-1 strategy, aiming to expand its clinical-stage programs and leverage its OPERA platform to address unmet clinical needs, with expectations to fund operations into 2027.